Author

A. L. Kung

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2

Frequent Co-Authors

F. S. Dela Cruz· 3 shared Y. Kuwahara· 3 shared A. Califano· 2 shared A. Kentsis· 2 shared D. Cameron· 2 shared E. De Stanchina· 2 shared H. S. Mueller· 2 shared M. Gounder· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. S. Dela Cruz

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Y. Kazansky, H. S. Mueller, D. Cameron, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, P. S. Mundi, Y. Kuwahara, R. Somwar, R. Qu, A. Califano, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, , A. Kentsis

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

bioRxiv · May 3, 2024Cancer Biology

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

Y. Kazansky, D. Cameron, H. S. Mueller, P. Demarest, N. Zaffaroni, N. Arrighetti, V. Zuco, Y. Kuwahara, R. Somwar, M. Ladanyi, R. Qu, E. De Stanchina, F. S. Dela Cruz, A. L. Kung, M. Gounder, A. Kentsis

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

bioRxiv · Feb 6, 2023Cancer Biology

Subclonal somatic copy number alterations emerge and dominate in recurrent osteosarcoma

M. D. Kinnaman, S. Zaccaria, A. Makohon-Moore, B. Arnold, M. Levine, G. Gundem, J. E. A. Ossa, D. Glodzik, M. I. R. Sanchez, N. Bouvier, S. Li, E. Stockfisch, M. Dunigan, C. Cobbs, U. Bhanot, , C. A. Iacobuzio-Donahue

This study identifies subclonal copy number alterations in relapsed osteosarcoma, showing MYC gain/amplification in treatment-resistant clones and their emergence before chemotherapy.

bioRxiv · Jan 5, 2023 · PreprintCancer Biology

Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors - expanding patient-driven discovery beyond the Nof1.

L. J. Marks, D. Diolaiti, P. Mundi, E. S. Gaviria, A. R. Rainey, D. J. Yamashiro, L. Fazlollahi, H. Hosoi, Y. Katsumi, Y. Kuwahara, F. S. Dela Cruz, A. Califano, A. L. Kung

This study identifies XPO1 activation as a non-genetic vulnerability in malignant rhabdoid tumors using patient-driven discovery and validates selinexor as a potential therapeutic.

bioRxiv · Oct 2, 2021 · PreprintCancer Biology